Array ( [0] => WP_Term Object ( [term_id] => 16 [name] => UpRi (XMT-1536) [slug] => xmt-1536 [term_group] => 0 [term_taxonomy_id] => 16 [taxonomy] => category [description] => [parent] => 9 [count] => 17 [filter] => raw [cat_ID] => 16 [category_count] => 17 [category_description] => [cat_name] => UpRi (XMT-1536) [category_nicename] => xmt-1536 [category_parent] => 9 ) [1] => WP_Term Object ( [term_id] => 15 [name] => XMT-1522 [slug] => xmt-1522 [term_group] => 0 [term_taxonomy_id] => 15 [taxonomy] => category [description] => [parent] => 9 [count] => 4 [filter] => raw [cat_ID] => 15 [category_count] => 4 [category_description] => [cat_name] => XMT-1522 [category_nicename] => xmt-1522 [category_parent] => 9 ) [2] => WP_Term Object ( [term_id] => 17 [name] => XMT-1592 [slug] => xmt-1592 [term_group] => 0 [term_taxonomy_id] => 17 [taxonomy] => category [description] => [parent] => 9 [count] => 1 [filter] => raw [cat_ID] => 17 [category_count] => 1 [category_description] => [cat_name] => XMT-1592 [category_nicename] => xmt-1592 [category_parent] => 9 ) [3] => WP_Term Object ( [term_id] => 18 [name] => XMT-1660 [slug] => xmt-1660 [term_group] => 0 [term_taxonomy_id] => 18 [taxonomy] => category [description] => [parent] => 9 [count] => 2 [filter] => raw [cat_ID] => 18 [category_count] => 2 [category_description] => [cat_name] => XMT-1660 [category_nicename] => xmt-1660 [category_parent] => 9 ) [4] => WP_Term Object ( [term_id] => 19 [name] => XMT-2056 [slug] => xmt-2056 [term_group] => 0 [term_taxonomy_id] => 19 [taxonomy] => category [description] => [parent] => 9 [count] => 4 [filter] => raw [cat_ID] => 19 [category_count] => 4 [category_description] => [cat_name] => XMT-2056 [category_nicename] => xmt-2056 [category_parent] => 9 ) )

Array ( [99] => WP_Term Object ( [term_id] => 19 [name] => XMT-2056 [slug] => xmt-2056 [term_group] => 0 [term_taxonomy_id] => 19 [taxonomy] => category [description] => [parent] => 9 [count] => 4 [filter] => raw [cat_ID] => 19 [category_count] => 4 [category_description] => [cat_name] => XMT-2056 [category_nicename] => xmt-2056 [category_parent] => 9 ) [28] => WP_Term Object ( [term_id] => 18 [name] => XMT-1660 [slug] => xmt-1660 [term_group] => 0 [term_taxonomy_id] => 18 [taxonomy] => category [description] => [parent] => 9 [count] => 2 [filter] => raw [cat_ID] => 18 [category_count] => 2 [category_description] => [cat_name] => XMT-1660 [category_nicename] => xmt-1660 [category_parent] => 9 ) [25] => WP_Term Object ( [term_id] => 17 [name] => XMT-1592 [slug] => xmt-1592 [term_group] => 0 [term_taxonomy_id] => 17 [taxonomy] => category [description] => [parent] => 9 [count] => 1 [filter] => raw [cat_ID] => 17 [category_count] => 1 [category_description] => [cat_name] => XMT-1592 [category_nicename] => xmt-1592 [category_parent] => 9 ) [20] => WP_Term Object ( [term_id] => 16 [name] => UpRi (XMT-1536) [slug] => xmt-1536 [term_group] => 0 [term_taxonomy_id] => 16 [taxonomy] => category [description] => [parent] => 9 [count] => 17 [filter] => raw [cat_ID] => 16 [category_count] => 17 [category_description] => [cat_name] => UpRi (XMT-1536) [category_nicename] => xmt-1536 [category_parent] => 9 ) [10] => WP_Term Object ( [term_id] => 15 [name] => XMT-1522 [slug] => xmt-1522 [term_group] => 0 [term_taxonomy_id] => 15 [taxonomy] => category [description] => [parent] => 9 [count] => 4 [filter] => raw [cat_ID] => 15 [category_count] => 4 [category_description] => [cat_name] => XMT-1522 [category_nicename] => xmt-1522 [category_parent] => 9 ) )

XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab

American Association for Cancer Research (AACR)

Anti-tumor effect of XMT-1660, a B7-H4 targeting antibody drug conjugate, in an unselected panel of patient derived xenograft models of breast cancer

American Association for Cancer Research (AACR)

Tumor cell-targeted STING-agonist antibody-drug conjugates achieve potential anti-tumor activity by delivering STING agonist specifically to tumor cells and FcγRI-expressing subset of myeloid cells

American Association for Cancer Research (AACR)

UPLIFT (ENGOT-ov67/GOG-3048): A Pivotal Cohort of Upifitamab Rilsodotin (XMT-1536; UpRi), an NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Platinum-Resistant Ovarian Cancer

SGO 2022 Annual Meeting on Women’s Cancer

Updated Results From the Phase 1b Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer

SGO 2022 Annual Meeting on Women’s Cancer

UPGRADE: Phase 1 Combination Trial of the NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) Upifitamab Rilsodotin (UpRi; XMT-1536) in Patients With Ovarian Cancer

SGO 2022 Annual Meeting on Women’s Cancer

Optimizing the Dose of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC): Updated Analysis of a Phase 1b Expansion Study in Ovarian Cancer

SGO 2022 Annual Meeting on Women’s Cancer

STING-Agonist ADCs Targeting Tumor-Associated Antigens Coordinate Immune-Mediated Killing of Antigen-Negative Cancer Cells

Society for Immunotherapy of Cancer (SITC)

XMT-2056: Tumor-targeted Innate Immune Activation via a STING-agonist Antibody Drug Conjugate

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Site Specific Dolasynthen ADCs demonstrate consistent exposure across a wide range of drug-to-antibody ratios

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Interim Data from the Ovarian Cancer Expansion Cohort and Next Steps for UpRi Development Plan

Company Presentation

UpRi (NaPi2b) Diagnostic Development Path

Company Presentation

XMT-1660, a B7-H4-Targeted Dolasynthen Antibody-Drug Conjugate for the Treatment of Breast Cancer

American Association for Cancer Research (AACR)

XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity

American Association for Cancer Research (AACR)

Tumor cell-intrinsic STING pathway activation leads to robust induction of Type III Interferons and contributes to the anti-tumor activity elicited by STING agonism

American Association for Cancer Research (AACR)

Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect

Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research (AACR)

The Dolaflexin-based antibody-drug conjugate XMT-1536 targets the solid tumor lineage antigen SLC34A2/NaPi2b

Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research (AACR)

2021 Virtual Analyst & Investor Day

Company Presentation

Immunosynthen: STING-Agonist ADC Platform

Company Presentation

Tumor cell-intrinsic STING pathway is activated in the presence of cues from immune cells and contributes to the anti-tumor activity of tumor cell-targeted STING agonist antibody-drug conjugates

Society for Immunotherapy of Cancer (SITC)

Safety and Efficacy of XMT-1536 in Ovarian Cancer: A Subgroup Analysis from the Phase 1 Expansion Study of XMT-1536, a NaPi2b Antibody-Drug Conjugate

European Society of Medical Oncology (ESMO)

Tumor Targeting of a STING Agonist by Means of an Antibody-Drug Conjugate Induces Potent Anti-Tumor Immune Responses

Innate Immunity Stimulating Therapies Summit

Systemic Administration of STING Agonist Antibody-Drug Conjugates Elicit Potent Anti-Tumor Immune Responses with Minimal Induction of Circulating Cytokines

American Association for Cancer Research (AACR)

XMT-1592, a Site-Specific Dolasynthen-Based NaPi2b-Targeted Antibody-Drug Conjugate for the Treatment of Ovarian Cancer and Lung Adenocarcinoma

American Association for Cancer Research (AACR)

Phase 1 expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC)

American Society of Clinical Oncology (ASCO)

A Phase 1 study of XMT-1536 in patients with solid tumors likely to express NaPi2b: A summary of dose escalation

SGO 2020 Annual Meeting on Women’s Cancer

XMT-1536 Phase 1 Dose Escalation Study

Company Presentation

Tumor targeting of a STING agonist with an antibody drug conjugate elicits potent anti-tumor immune responses

Society for Immunotherapy of Cancer (SITC)

NaPi2b Expression in a Large Surgical Non-Small Cell Lung Cancer (NSCLC) Cohort

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Mersana’s Innovative ADC Platforms – World ADC Summit 2019

World ADC Summit

Simultaneous quantification of total antibody and antibody-conjugated drug for XMT-1522 in human plasma using immunocapture-liquid chromatography/mass spectrometry.

Journal of Pharmaceutical and Biomedical Analysis, Volume 174, 10 September 2019, Pages 441-449

Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b

American Society of Clinical Oncology (ASCO)

Dolasynthen: A Novel, Homogeneous Auristatin F Hydroxypropyl Amide Antibody-Drug Conjugate Platform

American Association for Cancer Research (AACR)

An Antibody-Drug Conjugate Carrying a Microtubule Inhibitor and a DNA Alkylator Exerts Both Mechanisms of Action on Tumor Cells

American Association for Cancer Research (AACR)

Target Expression/Efficacy Relationship of XMT-1522, a HER2-targeting Antibody Drug Conjugate (ADC), in an Unselected Series of Non-small Cell Lung Cancer (NSCLC) Primary Human Carcinoma Xenografts.

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Discovery of the novel, homogeneous payload platform Dolasynthen for Antibody-Drug Conjugates

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Indole-Biaryl Pyrrolobenzodiazepines (I-BiPs): A Potent and Well-tolerated Class of DNA Mono-alkylating Payload for Antibody-Drug Conjugates (ADCs)

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

MERS67 is a Novel anti-NaPi2b Antibody and Demonstrates Differential Expression Patterns in Lung Cancer Histologic Subtypes

International Association for the Study of Lung Cancer (IASLC)

Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients with HER2-expressing breast, lung and gastric cancer

American Society of Clinical Oncology (ASCO)

Unique Pharmacological Properties of Dolaflexin-Based ADCs – A Controlled Bystander Effect

American Association for Cancer Research (AACR)

UPGRADE: Phase 1 Combination Trial of the NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) Upifitamab Rilsodotin (UpRi; XMT-1536) in Patients With Ovarian Cancer

Combination of anti-HER2 ADC XMT-1522 and checkpoint inhibitor pembrolizumab for treatment of NSCLC in preclinical models